Indication of low-density lipoprotein apheresis in severe hypercholesterolemia and its atherosclerotic vascular complications: Dextran sulfate cellulose low-density lipoprotein apheresis

Therapeutic Apheresis

Volumn 7, Issue 3, 2003, Pages 345-349

  Keller, Christiane ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cholesterol; Coronary artery disease; Dextran sulfate cellulose apheresis; Low density lipoprotein; Low density lipoprotein apheresis

Indexed keywords

CELLULOSE ACETATE; DEXTRAN SULFATE; LOW DENSITY LIPOPROTEIN;

ALLERGIC DISEASE; APHERESIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD RHEOLOGY; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; HEART PROTECTION; HETEROZYGOTE; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; LIPOPROTEIN APHERESIS; LIPOPROTEIN BLOOD LEVEL; NAUSEA; OXIDATION; PRIORITY JOURNAL; THORAX PAIN; TREATMENT INDICATION; VOMITING;

BLOOD COMPONENT REMOVAL; CELLULOSE; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; DEXTRAN SULFATE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; PLASMAPHERESIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038148615     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00063.x     Document Type: Article

References (34)

1. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia treated by plasma exchange. Lancet 1975;i:1208-11.
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Scand Simvastatin Survival Study (4s). Lancet 1994;344:1383-9.
3. Sacks SM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
4. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
5. Gordon BR, Kelsey SF, Dau PC et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1998;81:407-11.
6. Seidel D, Armstrong VW, Schuff-Werner P and the HELP Study Group. The HELP LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Invest 1991;24:724-32.
7. Bosch T, Lennertz A, Schmidt B et al. DALI Apheresis in hyperlipidemic patients: Biocompatibility, efficacy and selectivity of direct adsorption of lipoproteins from whole blood. Artif Organs 2000;24:81-90.
8. Keller C, Gruetzmacher P, Bahr F et al. LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors. Lancet 1993;340:60-1.
9. Kojima S, Shida M, Takano H et al. Effects of losartan on blood pressure and humoral factors in a patient who suffered from anaphylactoid reactions when treated with ACE inhibitors during LDL apheresis. Hypertension Res 2001;24:595-8.
10. Leong AS, Disney APS, Gove DW. Spallation and migration of silicone from blood-pump tubing in patients on dialysis. N Engl J Med 1982;306:135-40.
11. Matic GB, Martins K, Ahrenholz P et al. Release of microparticles in LDL apheresis. Transfusion Apheresis Sci 2001;24:129-33.
12. Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998;82:1489-95.
13. Yamamoto A, Harada-Shiba M, Kawaguchi A et al. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis 2000;153:89-98.
14. Bambauer R. Low-density lipoprotein apheresis: Results with different methods. Artif Organs 2002;26:133-44.
15. Maher VMG, Kitano Y, Neuwirth C et al. Effective reduction of plasma LDL levels by LDL-apheresis in familial defective apolipoprotein B-100. Atherosclerosis 1992;95:231-4.
16. Kobayashi J, Katsube S, Shimoda M et al. Single LDL-apheresis improves remnant-like particle-cholesterol. C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clin Chito Acta 2002;321:107-12.
17. 13C]leucine infusion in normal volunteers. Eur J Clin Invest 1993;23:602-14.
18. Parhofer KG, Barrett PH, Demant T et al. Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia. J Lipid Res 1996;37:2382-93.
19. Pfohl M, Naoumova RP, Klass C et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or witout concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 1994;35:1946-55.
20. Maugeais C, Ouguerram K, Frénais R et al. Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia. J Clin Endocrinol Metabol 2001;86:1679-86.
21. Marais AD, Naoumova RP, Firth JC et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997;38:2071-8.
22. Lasunción MA, Teruel JL, Alvarez JJ et al. Changes in lipoprotein (a), LDL cholesterol and apolipoprotein B in homozygous familial hypercholesterolaemic patients treated with dextran sulfate LDL-apheresis. Eur J Clin Invest 1993;23:819-26.
23. Kojima S. Low-density lipoprotein apheresis and changes in plasma components. Ther Apher 2001;5:232-40.
24. Empen K, Otto C, Brödl U et al. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J Clin Apheresis 2002;17:38-43.
25. Leitinger N, Pirich Ch, Blazek I et al. Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextransulfate LDL-apheresis treatment. Atherosclerosis 1996;126:305-12.
26. Stefanutti C, Di Giacomo S, Vivenzio A et al. Acute and long-term effects of low-density lipoprotein (LDL) -apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolemia. Clin Sci 2001;100:191-8.
27. Linseisen J, Wilhelm M, Hoffmann J et al. Acute effects of LDL-apheresis on cholesterol oxidation products and antioxidants in plasma and lipoproteins of patients with familial hypercholesterolemia. Eur J Med Res 1999;4:433-41.
28. Rubba P, Iannuzzi A, Postiglione A et al. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation 1990;81:610-16.
29. Aengevaeren WRM, Kroon AA, Stalenhoef AFH et al. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. The LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996;28:1696-704.
30. Kroon AA, Aengevaeren WRM, van der Werf T et al. LDL-apheresis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
31. Tatami R, Inoue N, Itoh H et al. Regression of coronary artery atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992;95:1-13.
32. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. BMJ 1985;291:1671-3.
33. Thompson GR, Maher VMG, Mattews S et al. Familial hypercholesterolaemia regression study: a randomized trial of low-density lipoprotein apheresis. Lancet 1995;345:811-16.
34. Kitabatake A, Sato H, Hori M et al. Coronary atherosclerosis is reduced in patients with familial hypocholesterolemia after intensive cholesterol lowering with low-density lipoprotein apheresis: 1-year follow-up study. Clin Ther 1994;16:41628.